Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
281 hedge funds and large institutions have $5.14B invested in Blueprint Medicines in 2021 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 109 increasing their positions, 72 reducing their positions, and 35 closing their positions.
54% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 35
51% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 72
7% more funds holding
Funds holding: 263 → 281 (+18)
0.71% less ownership
Funds ownership: 100.96% → 100.24% (-0.71%)
10% less capital invested
Capital invested by funds: $5.69B → $5.14B (-$550M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
39% less call options, than puts
Call options by funds: $8.99M | Put options by funds: $14.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$62.4M |
| 2 |
Morgan Stanley
New York
|
+$43.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$39.4M |
| 4 |
CCM
Cadian Capital Management
New York
|
+$37.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$29.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$263M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$110M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$31.9M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$20.7M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$11.3M |
BPMC Hedge Fund Activity: Q2 2021 in Review
281 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2021, worth a combined $5.14B — down 9.7% from $5.69B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BPMC positions and 35 closed out — a net gain of 19 holders — while 109 added to existing stakes and 72 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $62.4M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $263M sold.
- 281 institutional investors held Blueprint Medicines (BPMC) as of Q2 2021, up from 263 in Q1 2021.
- Funds reported $5.14B of Blueprint Medicines stock for Q2 2021, down 9.7% quarter-over-quarter.
- 54 funds opened new Blueprint Medicines positions in Q2 2021 and 35 closed out, a net change of +19 holders.
- The largest Blueprint Medicines buyer in Q2 2021 was Wellington Management Group, an estimated $62.4M added.
- The largest Blueprint Medicines seller in Q2 2021 was Lone Pine Capital, an estimated $263M sold.
Based on aggregated 13F filings for Q2 2021.